{"id":"biib014","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL447664","moleculeType":"Small molecule","molecularWeight":"321.34"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to CD20 on the surface of B cells, leading to their depletion and subsequent reduction in disease activity.","oneSentence":"BIIB014 is a monoclonal antibody targeting CD20.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:51.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT00451815","phase":"PHASE2","title":"BIIB014 Phase 2a Monotherapy","status":"WITHDRAWN","sponsor":"Biogen","startDate":"","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01017666","phase":"PHASE1","title":"BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-11-01","conditions":"Healthy","enrollment":28},{"nctId":"NCT01035515","phase":"PHASE1","title":"BIIB014 Cardiovascular Monitoring Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT00438607","phase":"PHASE2","title":"Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-04","conditions":"Parkinson's Disease","enrollment":83},{"nctId":"NCT00442780","phase":"PHASE2","title":"Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-08","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT00531193","phase":"PHASE1","title":"Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-09","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BIIB014","genericName":"BIIB014","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BIIB014 is a monoclonal antibody targeting CD20. Used for Relapsed or refractory non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}